NASDAQ:REPH - Recro Pharma Stock Price, Price Target & More

$11.69 +0.20 (+1.74 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$11.49
Today's Range$11.33 - $11.82
52-Week Range$5.81 - $12.23
Volume136,088 shs
Average Volume205,063 shs
Market Capitalization$224.04 million
P/E Ratio-5.82
Dividend YieldN/A
Beta-0.75

About Recro Pharma (NASDAQ:REPH)

Recro Pharma logoRecro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. It also develops Dex-IN, an intranasal formulation of dexmedetomidine for treating post-operative pain and peri-procedural pain; two novel neuromuscular blocking agents and a related proprietary chemical reversal agent; and Fadolmidine for use in as human therapeutic. The company also provides contract development and manufacturing services. Recro Pharma, Inc. has a license agreement with Orion Corporation for the development and commercialization of Dexmedetomidine. It focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Debt-to-Equity Ratio1.86%
Current Ratio1.75%
Quick Ratio1.55%

Price-To-Earnings

Trailing P/E Ratio-5.82
Forward P/E Ratio-3.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.83 million
Price / Sales3.17
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book7.74

Profitability

EPS (Most Recent Fiscal Year)($1.99)
Net Income$-50,080,000.00
Net Margins-69.61%
Return on Equity-75.97%
Return on Assets-21.65%

Miscellaneous

Employees256
Outstanding Shares19,500,000

How to Become a New Pot Stock Millionaire

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma (NASDAQ:REPH) announced its quarterly earnings data on Tuesday, February, 27th. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.22. The specialty pharmaceutical company had revenue of $19.04 million for the quarter, compared to the consensus estimate of $12.88 million. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%. View Recro Pharma's Earnings History.

What price target have analysts set for REPH?

7 brokers have issued 1 year price targets for Recro Pharma's stock. Their forecasts range from $6.50 to $20.00. On average, they expect Recro Pharma's share price to reach $15.10 in the next twelve months. View Analyst Ratings for Recro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a drop in short interest during the month of March. As of March 15th, there was short interest totalling 725,024 shares, a drop of 23.2% from the February 28th total of 943,682 shares. Based on an average daily trading volume, of 475,215 shares, the days-to-cover ratio is currently 1.5 days. Currently, 4.9% of the shares of the stock are short sold.

Who are some of Recro Pharma's key competitors?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, CEO, Pres & Director (Age 66)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 59)
  • Mr. Frederick H. Graff, Chief Commercial Officer (Age 68)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 41)
  • Mr. Randall J. Mack, Sr. VP of Devel. and Corp. Sec. (Age 53)

Has Recro Pharma been receiving favorable news coverage?

News headlines about REPH stock have trended somewhat positive this week, according to Accern. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Recro Pharma earned a coverage optimism score of 0.17 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 47.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BROADFIN CAPITAL, LLC (11.67%), STONEPINE CAPITAL MANAGEMENT, LLC (0.50%) and STONEPINE CAPITAL MANAGEMENT, LLC (0.50%). Company insiders that own Recro Pharma stock include Alfred Altomari, Donna Nichols, Healthcare Master Fun Broadfin, James E Flynn, Karen Flynn, Randall Mack, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp, Stewart Mccallum, Stonepine Capital Management, and Winston J Churchill. View Institutional Ownership Trends for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $11.69.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $224.04 million and generates $71.83 million in revenue each year. The specialty pharmaceutical company earns $-50,080,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Recro Pharma employs 256 workers across the globe.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (REPH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  304
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Recro Pharma (NASDAQ:REPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Recro Pharma in the last 12 months. Their average twelve-month price target is $15.10, suggesting that the stock has a possible upside of 29.17%. The high price target for REPH is $20.00 and the low price target for REPH is $6.50. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.752.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.10$14.4167$12.1250$13.50
Price Target Upside: 29.17% upside30.23% upside40.50% upside80.72% upside

Recro Pharma (NASDAQ:REPH) Consensus Price Target History

Price Target History for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018Berenberg BankInitiated CoverageBuyLowView Rating Details
4/5/2018OppenheimerReiterated RatingBuyHighView Rating Details
2/14/2018CIBCInitiated CoverageOutperform -> Outperform$19.00HighView Rating Details
2/13/2018UBSInitiated CoverageOutperformHighView Rating Details
10/27/2017Piper JaffrayReiterated RatingBuy$11.00N/AView Rating Details
7/31/2017Roth CapitalSet Price TargetBuy$20.00LowView Rating Details
6/14/2017Janney Montgomery ScottDowngradeBuy -> Fair Value$21.00 -> $6.50HighView Rating Details
3/27/2017AegisReiterated RatingBuy$11.00LowView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$19.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Recro Pharma (NASDAQ:REPH) Earnings History and Estimates Chart

Earnings by Quarter for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.54)($0.54)($0.54)
Q2 20181($0.56)($0.56)($0.56)
Q3 20181($0.79)($0.79)($0.79)
Q4 20181($0.61)($0.61)($0.61)

Recro Pharma (NASDAQ REPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018Q4 2017($0.85)($0.63)$12.88 million$19.04 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.75)($0.48)$13.93 million$17.11 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.54)($0.48)$14.90 million$16.93 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.5750)($0.42)$15.58 million$18.74 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.96)($0.81)$13.25 million$17.36 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.71)($0.50)$13.50 million$16.95 millionViewN/AView Earnings Details
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13$13.00 million$16.75 millionViewN/AView Earnings Details
11/13/2015Q3($0.20)($0.24)$16.54 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.17)$18.66 millionViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Recro Pharma (NASDAQ:REPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Recro Pharma (NASDAQ REPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.90%
Institutional Ownership Percentage: 57.09%
Insider Trading History for Recro Pharma (NASDAQ:REPH)
Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ REPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/13/2018Healthcare Master Fun BroadfinMajor ShareholderSell200,000$10.07$2,014,000.00View SEC Filing  
1/3/2018Scp Vitalife Partners (Israel)Major ShareholderSell12,964$8.88$115,120.32734,269View SEC Filing  
12/29/2017Scp Vitalife Partners Ii LpMajor ShareholderSell18,231$9.27$169,001.37View SEC Filing  
12/28/2017Scp Vitalife Partners (Israel)Major ShareholderSell1,980$9.44$18,691.20744,708View SEC Filing  
12/27/2017Scp Vitalife Partners Ii LpMajor ShareholderSell13,189$9.56$126,086.842,243,064View SEC Filing  
12/21/2017Healthcare Master Fun BroadfinMajor ShareholderSell76,000$9.87$750,120.00View SEC Filing  
12/13/2017Healthcare Master Fun BroadfinMajor ShareholderSell93,237$9.86$919,316.82View SEC Filing  
12/5/2017Healthcare Master Fun BroadfinMajor ShareholderSell100,000$10.00$1,000,000.00View SEC Filing  
11/30/2017Healthcare Master Fun BroadfinMajor ShareholderSell222,616$9.58$2,132,661.28View SEC Filing  
11/28/2017Healthcare Master Fun BroadfinMajor ShareholderSell47,549$9.64$458,372.36View SEC Filing  
11/24/2017Healthcare Master Fun BroadfinMajor ShareholderSell172,208$9.45$1,627,365.60View SEC Filing  
11/21/2017Healthcare Master Fun BroadfinMajor ShareholderSell102,440$9.50$973,180.00View SEC Filing  
6/14/2017James E FlynnInsiderSell110,447$6.39$705,756.33View SEC Filing  
6/13/2017James E FlynnMajor ShareholderSell32,447$6.59$213,825.73View SEC Filing  
6/12/2017James E FlynnMajor ShareholderSell10,000$6.74$67,400.00View SEC Filing  
6/8/2017James E FlynnInsiderSell62,868$7.06$443,848.08View SEC Filing  
5/12/2017Stonepine Capital Management,Major ShareholderSell510,000$7.40$3,774,000.00View SEC Filing  
5/11/2017Stonepine Capital Management,Major ShareholderSell244,629$7.65$1,871,411.85View SEC Filing  
5/4/2017Stonepine Capital Management,Major ShareholderSell217,308$7.70$1,673,271.60View SEC Filing  
3/16/2017Scp Vitalife Partners Ii LpMajor ShareholderSell44,977$8.00$359,816.002,276,571View SEC Filing  
2/17/2017Scp Vitalife Partners Ii LpMajor ShareholderSell9,983$7.59$75,770.972,292,899View SEC Filing  
2/16/2017Scp Vitalife Partners (Israel)Major ShareholderSell4,030$7.89$31,796.70772,714View SEC Filing  
12/16/2016Karen FlynnDirectorBuy800$6.71$5,368.00800View SEC Filing  
12/15/2016Alfred AltomariDirectorBuy1,500$6.55$9,825.001,500View SEC Filing  
12/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy650,000$6.00$3,900,000.00View SEC Filing  
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.001,000View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.002,000View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90776,131View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60783,642View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.202,340View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.002,349,511View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00788,847View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Recro Pharma (NASDAQ REPH) News Headlines

Source:
DateHeadline
Berenberg Starts Recro Pharma (REPH) at BuyBerenberg Starts Recro Pharma (REPH) at Buy
www.streetinsider.com - April 20 at 5:11 PM
Recro Pharma (REPH) Now Covered by Analysts at Berenberg BankRecro Pharma (REPH) Now Covered by Analysts at Berenberg Bank
www.americanbankingnews.com - April 19 at 11:46 AM
Recro Pharma (REPH) Downgraded to "Hold" at Zacks Investment ResearchRecro Pharma (REPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 4:44 PM
Recro Pharma (REPH) Rating Increased to Buy at ValuEngineRecro Pharma (REPH) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - April 18 at 1:24 PM
Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine MeetingRecro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
feeds.benzinga.com - April 16 at 7:46 AM
Zacks: Brokerages Expect Recro Pharma Inc (REPH) Will Announce Quarterly Sales of $17.32 MillionZacks: Brokerages Expect Recro Pharma Inc (REPH) Will Announce Quarterly Sales of $17.32 Million
www.americanbankingnews.com - April 13 at 2:35 AM
 Analysts Expect Recro Pharma Inc (REPH) Will Post Earnings of -$0.68 Per Share Analysts Expect Recro Pharma Inc (REPH) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - April 11 at 3:10 PM
Exclusive: Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO BusinessExclusive: Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business
www.benzinga.com - April 7 at 4:20 PM
Recro Pharma (REPH) Earns Buy Rating from OppenheimerRecro Pharma (REPH) Earns Buy Rating from Oppenheimer
www.americanbankingnews.com - April 6 at 11:07 AM
Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO BusinessRecro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business
www.benzinga.com - April 5 at 5:06 PM
Recro Pharma Inc (REPH) Receives Consensus Recommendation of "Buy" from AnalystsRecro Pharma Inc (REPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 5:34 PM
Short Interest in Recro Pharma Inc (REPH) Decreases By 23.2%Short Interest in Recro Pharma Inc (REPH) Decreases By 23.2%
www.americanbankingnews.com - March 31 at 1:45 AM
Zacks Investment Research Lowers Recro Pharma (REPH) to SellZacks Investment Research Lowers Recro Pharma (REPH) to Sell
www.americanbankingnews.com - March 29 at 1:58 PM
Active-Investors: Wired News - Recro Pharma Publishes Data from Phase-III Trial for IV MeloxicamActive-Investors: Wired News - Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam
www.finanznachrichten.de - March 29 at 8:44 AM
Wired News – Recro Pharma Publishes Data from Phase-III Trial for IV MeloxicamWired News – Recro Pharma Publishes Data from Phase-III Trial for IV Meloxicam
finance.yahoo.com - March 29 at 8:44 AM
Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of PainRecro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain
finance.yahoo.com - March 27 at 8:45 AM
Zacks: Brokerages Anticipate Recro Pharma Inc (REPH) Will Announce Quarterly Sales of $17.32 MillionZacks: Brokerages Anticipate Recro Pharma Inc (REPH) Will Announce Quarterly Sales of $17.32 Million
www.americanbankingnews.com - March 27 at 3:40 AM
 Analysts Anticipate Recro Pharma Inc (REPH) Will Announce Earnings of -$0.68 Per Share Analysts Anticipate Recro Pharma Inc (REPH) Will Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - March 25 at 5:15 PM
Recro Pharma (REPH) Given "Buy" Rating at OppenheimerRecro Pharma (REPH) Given "Buy" Rating at Oppenheimer
www.americanbankingnews.com - March 23 at 6:36 PM
Recro Pharma (REPH) Upgraded to "Hold" by Zacks Investment ResearchRecro Pharma (REPH) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 21 at 1:29 PM
Recro Pharma to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)Recro Pharma to Present at the 17th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:16 AM
Recro Pharma to Present at the 17th Annual Needham Healthcare ConferenceRecro Pharma to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 9:16 AM
Healthcare Master Fun Broadfin Sells 200,000 Shares of Recro Pharma Inc (REPH) StockHealthcare Master Fun Broadfin Sells 200,000 Shares of Recro Pharma Inc (REPH) Stock
www.americanbankingnews.com - March 15 at 7:28 PM
Recro Pharma Inc (REPH) Given Consensus Rating of "Buy" by BrokeragesRecro Pharma Inc (REPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 10 at 5:39 PM
Recro Pharma Inc (REPH) Stake Lessened by Stonepine Capital Management LLCRecro Pharma Inc (REPH) Stake Lessened by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 2:53 PM
Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in ... - GlobeNewswire (press release)Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 8:36 AM
Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual MeetingRecro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
finance.yahoo.com - March 5 at 8:36 AM
Brokers Offer Predictions for Recro Pharma Incs Q1 2018 Earnings (REPH)Brokers Offer Predictions for Recro Pharma Inc's Q1 2018 Earnings (REPH)
www.americanbankingnews.com - March 5 at 1:46 AM
Recro Pharma (REPH) Upgraded to "Hold" at ValuEngineRecro Pharma (REPH) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 4 at 3:19 PM
Recro Pharma Announces Commercial Team Additions - GlobeNewswire (press release)Recro Pharma Announces Commercial Team Additions - GlobeNewswire (press release)
www.globenewswire.com - March 3 at 6:09 PM
Recro Pharma Announces Commercial Team Additions Nasdaq ... - GlobeNewswire (press release)Recro Pharma Announces Commercial Team Additions Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 6:09 PM
Recro Pharma Inc (REPH) Files 10-K for the Fiscal Year Ended on December 31, 2017Recro Pharma Inc (REPH) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - March 3 at 8:31 AM
Recro Pharma Announces Commercial Team AdditionsRecro Pharma Announces Commercial Team Additions
finance.yahoo.com - March 2 at 5:53 PM
Recro Pharma Inc Expected to Earn FY2020 Earnings of $0.82 Per Share (REPH)Recro Pharma Inc Expected to Earn FY2020 Earnings of $0.82 Per Share (REPH)
www.americanbankingnews.com - March 2 at 4:54 PM
Recro Pharma Inc (REPH) Shares Sold by Broadfin Capital LLCRecro Pharma Inc (REPH) Shares Sold by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM
Recro Pharma Reports Year End 2017 Financial Results - GlobeNewswire (press release)Recro Pharma Reports Year End 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:28 AM
Recro Pharma (REPH) Given a $19.00 Price Target at OppenheimerRecro Pharma (REPH) Given a $19.00 Price Target at Oppenheimer
www.americanbankingnews.com - February 28 at 6:18 PM
Recro Pharma Reports Year End 2017 Financial ResultsRecro Pharma Reports Year End 2017 Financial Results
finance.yahoo.com - February 27 at 8:37 AM
Recro Pharma (REPH) Reports Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain ResearchRecro Pharma (REPH) Reports Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
www.streetinsider.com - February 21 at 8:36 AM
Recro Pharma to Host Analyst and Investor Day on February 28, 2018Recro Pharma to Host Analyst and Investor Day on February 28, 2018
finance.yahoo.com - February 21 at 8:36 AM
$12.88 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter$12.88 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter
www.americanbankingnews.com - February 21 at 5:40 AM
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain ResearchRecro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
finance.yahoo.com - February 20 at 8:28 AM
-$0.91 Earnings Per Share Expected for Recro Pharma Inc (REPH) This Quarter-$0.91 Earnings Per Share Expected for Recro Pharma Inc (REPH) This Quarter
www.americanbankingnews.com - February 19 at 5:16 PM
Recro Pharma Inc (REPH) to Post FY2017 Earnings of ($2.43) Per Share, Oppenheimer ForecastsRecro Pharma Inc (REPH) to Post FY2017 Earnings of ($2.43) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - February 16 at 6:26 AM
Recro Pharma (REPH) Earns Outperform Rating from Analysts at CIBCRecro Pharma (REPH) Earns Outperform Rating from Analysts at CIBC
www.americanbankingnews.com - February 14 at 12:58 PM
Recro Pharma (REPH) Earns Outperform Rating from Analysts at UBS GroupRecro Pharma (REPH) Earns Outperform Rating from Analysts at UBS Group
www.americanbankingnews.com - February 13 at 8:40 PM
Recro Pharma Inc (REPH) Given Average Rating of "Buy" by BrokeragesRecro Pharma Inc (REPH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 7:48 PM
Recro Pharma (REPH) Now Covered by Analysts at OppenheimerRecro Pharma (REPH) Now Covered by Analysts at Oppenheimer
www.americanbankingnews.com - February 13 at 6:28 PM
$13.32 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter$13.32 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter
www.americanbankingnews.com - February 4 at 2:40 AM
Recro Pharma Announces Key Sales Team Additions Nasdaq:REPH - GlobeNewswire (press release)Recro Pharma Announces Key Sales Team Additions Nasdaq:REPH - GlobeNewswire (press release)
globenewswire.com - February 3 at 3:56 PM

SEC Filings

Recro Pharma (NASDAQ:REPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Recro Pharma (NASDAQ:REPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Recro Pharma (NASDAQ REPH) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.